Oxalic Acid

Oxalic Acid

SCHEMBL4079200

CCn1cnc(CCN)c1.O=C(O)C(=O)O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 15/20 0.56
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
TSHR P16473 1/20 0.50
MTOR P42345 1/20 0.50
HRH4 Q9H3N8 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
TDP1 Q9NUW8 1/20 0.49
CPB1 P15086 6/20 0.45
SMYD3 Q9H7B4 1/20 0.38
MAP3K5 Q99683 1/20 0.36
CYP2E1 P05181 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2A6 P11509 1/20 0.36
CYP2B6 P20813 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL589342 0.90 CYP2C9 (0.60) CPB2CYP2C9CYP2C19TSHRMTOR
SCHEMBL7278477 0.80 CPB2 (0.48) CPB2CYP2C9CYP2C19CPB1SMYD3
SCHEMBL239541 0.80 CYP2C9 (0.49) CPB2CYP2C9CYP2C19TSHRMTOR
Hydrochloric Acid SCHEMBL9803746 0.79 TDP1 (0.50) CPB2CYP2C9CYP2C19TSHRMTOR
SCHEMBL1441194 0.76 CPB2 (0.50) CPB2CYP2C9CYP2C19TDP1CPB1
SCHEMBL1887218 0.76 CYP2C9 (0.61) CPB2CYP2C9CYP2C19TSHRMTOR
SCHEMBL28875894 0.75 CYP2C9 (0.55) CPB2CYP2C9CYP2C19TSHRMTOR
SCHEMBL27747749 0.75 CYP2C9 (0.47) CPB2CYP2C9CYP2C19TSHRMTOR
SCHEMBL24329576 0.75
SCHEMBL10566 0.75 CPB2 (0.41) CPB2CYP2C9CYP2C19TSHRMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354418-B2 Thiazolyl-dihydro-quinazolines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-15 US disclosed
CN-101460508-A Thiazolyl-dihydro-chinazoline BOEHRINGER INGELHEIM INT (DE) 2009-06-17 CN disclosed
CN-101460507-A Thiazolyldihydroindazoles BOEHRINGER INGELHEIM INT (DE) 2009-06-17 CN disclosed
US-20090131424-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-21 US disclosed
US-7517995-B2 Thiazolyl-dihydro-cyclopentapyrazole BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-14 US disclosed
US-20070259855-A1 THIAZOLYL-DIHYDRO-INDAZOLE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-11-08 US disclosed
US-20070238746-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed
US-20070238730-A1 THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259855-A1 THIAZOLYL-DIHYDRO-INDAZOLE ROR1, RORB, RORA CPB2 4432/4885CYP2C9 14/4885CYP2C19 85/4885
US-20070238746-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE CYP3A7, UGT2B7, UGT1A7 CPB2 3114/4885CYP2C9 14/4885CYP2C19 204/4885
US-20090131424-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE CYP3A7, UGT2B7, UGT1A7 CPB2 3114/4885CYP2C9 14/4885CYP2C19 204/4885
US-20070238730-A1 THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE REN, ROR1, RORB CPB2 2939/4885CYP2C9 13/4885CYP2C19 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.